LENALIDOMIDE is an immunomodulatory drug that has antiangiogenic, and anti-inflammatory properties. It has shown an efficient anti-myeloma activity. Dexamethasone is a corticosteroid used to treat multiple myeloma (MM). This study aims to evaluate in-vitro and in-vivo the proliferation of myeloma cells after treatment with Lenalidomide, Dexamethasone, γ- irradiation and their combination. In-vitro studies: the treatment effect on the growth of myeloma cells with each of Lenalidomide (0.5-10 μM/ml) or Dexamethasone (10-100 nM/ml) or γ-irradiation (0.5-10 Gy), double combination of the two drugs (Lenalidomide + Dexamethasone) with different doses and triple combination of the two drugs with γ-irradiation doses (0.5-8 Gy) were carried out during 6 days. In-vivo studies: mice bearing ascites were treated with each of Lenalidomide, Dexamethasone or γ-irradiation, double combination of the two drugs and triple combination of the two drugs with γ-irradiation for 3 weeks. Different biochemical parameters were estimated before and after treatment to evaluate the antitumor activities such as β2-microglobulin, cell cycle analysis (flow cytometry), and caspase enzymes. In-vitro, treatment of myeloma cells with the triple combination (3 μM/ml Lenalidomide +40 nM/ml Dexamethasone + 3 Gy γ-irradiation) has inhibited the growth of myeloma cells within 4 days. In-vivo, in mice bearing ascites, the triple combination inhibited the growth and decreased the viability % of tumor cells to zero% within 2 weeks. The results obtained from the study of the effective doses showed a reduction in the concentrations of β2-Microglobulins and activation of the levels of caspase 8 and caspase 9 causing a control of the cell cycle. Treatment of myeloma cells with dual therapy (Lenalidomide-Dexamethasone as a chemotherapy with γ-irradiation as a radiotherapy) resulted in a synergistic effect for treatment of multiple myeloma. This effect increases the growth inhibition, apoptosis, and regression of tumors compared to either treatment agent alone.
Elshershaby, H. M., Ebied, N., Abd el hameed, K., & Allahloubi, N. (2020). Synergistic Effect of some Chemotherapeutic Drugs with Gamma Radiation on the Proliferation of Myeloma Cells. Egyptian Journal of Radiation Sciences and Applications, 33(2), 89-100. doi: 10.21608/ejrsa.2020.44876.1104
MLA
Hanan M. Elshershaby; Nahed Ebied; Kamel Abd el hameed; Nasr Allahloubi. "Synergistic Effect of some Chemotherapeutic Drugs with Gamma Radiation on the Proliferation of Myeloma Cells". Egyptian Journal of Radiation Sciences and Applications, 33, 2, 2020, 89-100. doi: 10.21608/ejrsa.2020.44876.1104
HARVARD
Elshershaby, H. M., Ebied, N., Abd el hameed, K., Allahloubi, N. (2020). 'Synergistic Effect of some Chemotherapeutic Drugs with Gamma Radiation on the Proliferation of Myeloma Cells', Egyptian Journal of Radiation Sciences and Applications, 33(2), pp. 89-100. doi: 10.21608/ejrsa.2020.44876.1104
VANCOUVER
Elshershaby, H. M., Ebied, N., Abd el hameed, K., Allahloubi, N. Synergistic Effect of some Chemotherapeutic Drugs with Gamma Radiation on the Proliferation of Myeloma Cells. Egyptian Journal of Radiation Sciences and Applications, 2020; 33(2): 89-100. doi: 10.21608/ejrsa.2020.44876.1104
)
View on SCiNiTO